|Mr. Sandeep Laumas M.D.||CEO & Exec. Chairman||687.5k||N/A||1969|
|Mr. Jay P. Madan M.S.||Founder, Pres, Chief Bus. Officer & Director||688.08k||N/A||1966|
|Dr. Christopher P. Prior||Consultant||605k||N/A||1953|
|Dr. June S. Almenoff||Consultant||555.46k||N/A||1957|
|Mr. Edward J. Sitar||Chief Financial & Accounting Officer||N/A||N/A||1963|
Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.
Innovate Biopharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.